Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
Post-operative delirium is a common complication following cardiac surgery and is associated with increased 1 year mortality. Currently there are no drug therapies to prevent delirium. Orexin is a neuromodulator thought to play an important role in disordered sleep, one of the instigators of delirium. Lembrorexant is an orexin antagonist, originally approved for sleep, that may also reduce the incidence of delirium. The Investigators propose a pilot study to determine the feasibility of a randomized controlled trial comparing Lembrorexant to placebo in patients following cardiac surgery in reducing the incidence of delirium, and improving sleep.
Phase:
PHASE2
Details
Lead Sponsor:
University of British Columbia
Collaborators:
Eisai Inc. Providence Health Care, British Columbia St. Paul's Hospital, Vancouver (Providence Health Care)